Skip to main content

Advertisement

SpringerLink
Log in

A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The prognosis for advanced non-small cell lung cancer remains poor. Response to chemotherapy is infrequent and overall survival is low. Trans-retinoic acid (tRA), a differentiating agent whose mechanism of action is thought to be different from conventional chemotherapy has activity in preclinical models and low but definite activity in the clinical setting. Its use has been hampered by decrease in bioavailability during continuous administration. We used an interrupted dosing schedule with a drug holiday for tRA that has since been confirmed to restore blood levels in combination with chemotherapy (Cisplatin-VP 16) in 20 patients with stage IIIB and IV non-small cell lung cancer. Ten patients had partial responses among 19 evaluable pts (53%; 95% confidence interval 30–75%) and 4 had minor responses. Neutropenia was the most common acute toxicity-grade 3/4 neutropenia occurring in 90% of patients at some point in the treatment course. Median survival was 25.5 weeks.

This regimen of trans-retinoic acid given with drug holiday and chemotherapy has significant activity in advanced non-small cell lung cancer, is fairly well tolerated and is worthy of confirmation in a larger, multi-institutional setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA. A Cancer Journal for Clinicians 65:29–44, 1996

    Google Scholar 

  2. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327:1434–1441, 1992

    Google Scholar 

  3. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602–1613, 1989

    Google Scholar 

  4. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogels S: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 4:14–22, 1986

    Google Scholar 

  5. Munker M, Munker R, Saxton RE, Koeffler HP: Effect of recombinant monokines, lymphokines and other agents on clonal proliferation of human lung cancer cell lines. Cancer Res 47:4081–4085, 1987

    Google Scholar 

  6. Cowan JD, Von Hoff DD, Dinesman A, Clark G: Use of a human tumor cloning system to screen retinoids for antineoplastic activity. Cancer 51:92–96, 1983

    Google Scholar 

  7. Grunberg SM, Itri LM: Phase II study of Isotretinoin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 71(11):1097–1098, 1987

    Google Scholar 

  8. Meyskens FL Jr, Gilmartin E, Alberts DS, Levine NS, Brooks R, Slamon S, Surwit EA: Activity of isotretonoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep 66:1315–1319, 1982

    Google Scholar 

  9. Uphouse W, Oishi N, Berenberg J, Inamasu M, Tell D, Rundhaug J: Treatment of advanced non-small cell lung cancer with 13-cis-retinoic acid. Proc ASCO 6:712, 1987

    Google Scholar 

  10. Friedland D, Luginbuhl W, Meehan L, Gorman G, Kaiser L, Treat J: Phase II trial of all-trans-retinoic acid in metastatic non-small cell lung cancer. Proc ASCO 13:1086, 1994

    Google Scholar 

  11. Atiba JO, Manzardo A, Schell M, Thiruvengadam R, Prestfillippo J, Lutzky: Restoration of oral all-trans-retinoic acid (tRA) bioavailability: combination therapy with alpha interferon (ifn) versus a drug holiday. Proc ASCO 14:1484, 1994

    Google Scholar 

  12. Atiba JO, Manzardo AM, Thiruvengadam R, Schell MJ: Restoration of oral all-trans-retinoic acid bioavailability after a brief drug holiday. Am J Therap (in press), 1996

  13. Adamson PC, Bailey J, Pluda J et al.: Pharmacokinetic of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 13:1238–1241, 1995

    Google Scholar 

  14. Bailey J, Pluda JM, Foli A, Saville MW, Bauza S, Adamson PC, Murphy RF, Cohen RB, Broder S, Yarchoan R: Phase I/II study of intermittent all-trans-retinoic acid alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 13(8):1966–1974, 1995

    Google Scholar 

  15. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, Reynolds CP: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13(4):894–901, 1995

    Google Scholar 

  16. Niesvizky R, Siegel DS, Busquets X, Nichols G, Muindi J, Warrell RP Jr, Michaeli J: Hypercalceamia and increased serum interleukin-6 levels induced by all-trans-retinoic acid in patients with multiple myeloma. Br J Haematol 89(1):217–218, 1995

    Google Scholar 

  17. Merryman JI, Capen CC, McCauley LK, Werkmeister JR, Suter MM, Rosol TJ: Regulation of parathyroid hormone-related protein production by a squamous carcinoma cell line in vitro. Lab Invest 69(3):347–354, 1993

    Google Scholar 

  18. Sakakibara M, Ichikawa M, Amano Y, Matsuzawa S, Agematsu K, Mori T, Koike K, Nakahata T, Komiyama A: Hypercalcemia associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia Res 17(5):441–443, 1993

    Google Scholar 

  19. Lemez P: Hypercalcaemia caused by all-trans-retinoicoid acid (ATRA) treatment in a case of acute promyelocytic leukaemia was manageable after decreasing the ATRA dose to 27 mg/m2/day. Eur J Haematol 55(4):275–276, 1995

    Google Scholar 

  20. Suzumiya J, Asahara F, Katakami H, Kimuran N, Hisano S, Okumura M, Ohno R: Hypercalcaemia caused by all-transretinoic acid treatment of acute promyelocytic leukaemia: case report (letter). Eur J Haematol 53(2):126–127, 1994

    Google Scholar 

  21. Nagasawa M, Okawa H: All-trans-retinoic acid induced hypercalcemia in a patient with acute promyelocytic leukemia: its relation to increased PTH-rP (letter). Int J Haematol 59(2):143–144, 1994

    Google Scholar 

  22. Villablanca JG, Khan AA, Avramis VI, Reynolds CP: Hypercalcemia: a dose-limiting toxicity associated with 13-cisretinoic acid. Am J Pediat Hematol/Oncol 15(4):410–415, 1993

    Google Scholar 

  23. Akiyama H, Nakamura N, Nagasaka S, Sakamaki H, Onozawa Y: Hypercalcaemia due to all-trans-retinoic acid (letter). Lancet 339(8788):308–309, 1992

    Google Scholar 

  24. Kahn MJ, Luginbuhl W, Gaines L, Bratschi J, Bavaria J, Kaiser L, Treat J: Leukocytosis associated with all-trans-retinoic acid in metastatic non-small cell lung cancer (letter). J Natl Cancer Inst 84(21):1669–1671, 1992

    Google Scholar 

  25. Muindi J, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP Jr: Continuous treatment with all-trans-retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 79(2):299–303, 1992

    Google Scholar 

  26. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU, Hong WK: 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin (see Comments). J Natl Cancer Inst 84(4):235–241, 1992

    Google Scholar 

  27. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, Holdener E, Krakoff IH: 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84(4):241–245, 1992

    Google Scholar 

  28. Murphy WK, Fossella FV, Winn RJ et al.: A Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384–388, 1993

    Google Scholar 

  29. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom F, Litwin S, Ozols RF: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 13(8):1860–1870, 1995

    Google Scholar 

  30. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, Huber M, Perez-Soler R, Hong WK, Raber M: A Phase II trial of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12:1238–1244, 1994

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, VA Medical Center and University of California, Irvine

    Raghu Thiruvengadam, Joshua O. Atiba & Samar H. Azawi

  2. Department of Radiation Oncology, VA Medical Center, 90822, Long Beach, CA, USA

    Raghu Thiruvengadam, Joshua O. Atiba & Samar H. Azawi

Authors
  1. Raghu Thiruvengadam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua O. Atiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samar H. Azawi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thiruvengadam, R., Atiba, J.O. & Azawi, S.H. A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer. Invest New Drugs 14, 395–401 (1996). https://doi.org/10.1007/BF00180817

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00180817

Key words

Search

Navigation